{
 "cells": [
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "# GraphRAG Python package\n",
    "End-to-end-example on research papers. "
   ],
   "id": "cf0be1ddc2bd2434"
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "%%capture\n",
    "%pip install fsspec langchain-text-splitters openai python-dotenv numpy torch neo4j-graphrag-python"
   ],
   "id": "9820f541adf30bfd",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:37:53.429006Z",
     "start_time": "2024-10-12T23:37:53.420785Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "\n",
    "# load neo4j credentials (and openai api key in background)\n",
    "load_dotenv('.env', override=True)\n",
    "NEO4J_URI = os.getenv('NEO4J_URI')\n",
    "NEO4J_USERNAME = os.getenv('NEO4J_USERNAME')\n",
    "NEO4J_PASSWORD = os.getenv('NEO4J_PASSWORD')"
   ],
   "id": "a023c71324bf6e7f",
   "outputs": [],
   "execution_count": 1
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "## Knowledge Graph Building\n",
   "id": "418bd212bae7f492"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:37:54.152596Z",
     "start_time": "2024-10-12T23:37:53.430163Z"
    }
   },
   "cell_type": "code",
   "source": [
    "import neo4j\n",
    "from neo4j_graphrag.llm import OpenAILLM\n",
    "from neo4j_graphrag.embeddings.openai import OpenAIEmbeddings\n",
    "\n",
    "driver = neo4j.GraphDatabase.driver(NEO4J_URI, auth=(NEO4J_USERNAME, NEO4J_PASSWORD))\n",
    "\n",
    "ex_llm=OpenAILLM(\n",
    "    model_name=\"gpt-4o-mini\",\n",
    "    model_params={\n",
    "        \"response_format\": {\"type\": \"json_object\"}, # use json_object formatting for best results\n",
    "        \"temperature\": 0 # turning temperature down for more deterministic results\n",
    "    }\n",
    ")\n",
    "\n",
    "#create text embedder\n",
    "embedder = OpenAIEmbeddings()"
   ],
   "id": "fd60a2f512b9701d",
   "outputs": [],
   "execution_count": 2
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:37:54.156139Z",
     "start_time": "2024-10-12T23:37:54.153649Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#define node labels\n",
    "basic_node_labels = [\"Object\", \"Entity\", \"Group\", \"Person\", \"Organization\", \"Place\"]\n",
    "\n",
    "academic_node_labels = [\"ArticleOrPaper\", \"PublicationOrJournal\"]\n",
    "\n",
    "medical_node_labels = [\"Anatomy\", \"BiologicalProcess\", \"Cell\", \"CellularComponent\", \n",
    "                       \"CellType\", \"Condition\", \"Disease\", \"Drug\",\n",
    "                       \"EffectOrPhenotype\", \"Exposure\", \"GeneOrProtein\", \"Molecule\",\n",
    "                       \"MolecularFunction\", \"Pathway\"]\n",
    "\n",
    "node_labels = basic_node_labels + academic_node_labels + medical_node_labels\n",
    "\n",
    "# define relationship types\n",
    "rel_types = [\"ACTIVATES\", \"AFFECTS\", \"ASSESSES\", \"ASSOCIATED_WITH\", \"AUTHORED\",\n",
    "    \"BIOMARKER_FOR\", \"CAUSES\", \"CITES\", \"CONTRIBUTES_TO\", \"DESCRIBES\", \"EXPRESSES\",\n",
    "    \"HAS_REACTION\", \"HAS_SYMPTOM\", \"INCLUDES\", \"INTERACTS_WITH\", \"PRESCRIBED\",\n",
    "    \"PRODUCES\", \"RECEIVED\", \"RESULTS_IN\", \"TREATS\", \"USED_FOR\"]\n"
   ],
   "id": "6cba83fa4638e21d",
   "outputs": [],
   "execution_count": 3
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:37:55.823499Z",
     "start_time": "2024-10-12T23:37:55.820159Z"
    }
   },
   "cell_type": "code",
   "source": [
    "prompt_template = '''\n",
    "You are a medical researcher tasks with extracting information from papers \n",
    "and structuring it in a property graph to inform further medical and research Q&A.\n",
    "\n",
    "Extract the entities (nodes) and specify their type from the following Input text.\n",
    "Also extract the relationships between these nodes. the relationship direction goes from the start node to the end node. \n",
    "\n",
    "\n",
    "Return result as JSON using the following format:\n",
    "{{\"nodes\": [ {{\"id\": \"0\", \"label\": \"the type of entity\", \"properties\": {{\"name\": \"name of entity\" }} }}],\n",
    "  \"relationships\": [{{\"type\": \"TYPE_OF_RELATIONSHIP\", \"start_node_id\": \"0\", \"end_node_id\": \"1\", \"properties\": {{\"details\": \"Description of the relationship\"}} }}] }}\n",
    "\n",
    "- Use only the information from the Input text.  Do not add any additional information.  \n",
    "- If the input text is empty, return empty Json. \n",
    "- Make sure to create as many nodes and relationships as needed to offer rich medical context for further research.\n",
    "- An AI knowledge assistant must be able to read this graph and immediately understand the context to inform detailed research questions. \n",
    "- Multiple documents will be ingested from different sources and we are using this property graph to connect information, so make sure entity types are fairly general. \n",
    "\n",
    "Use only fhe following nodes and relationships (if provided):\n",
    "{schema}\n",
    "\n",
    "Assign a unique ID (string) to each node, and reuse it to define relationships.\n",
    "Do respect the source and target node types for relationship and\n",
    "the relationship direction.\n",
    "\n",
    "Do not return any additional information other than the JSON in it.\n",
    "\n",
    "Examples:\n",
    "{examples}\n",
    "\n",
    "Input text:\n",
    "\n",
    "{text}\n",
    "'''"
   ],
   "id": "8cbcdedcd1757b1d",
   "outputs": [],
   "execution_count": 4
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:37:57.618402Z",
     "start_time": "2024-10-12T23:37:57.518596Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.experimental.components.text_splitters.fixed_size_splitter import FixedSizeSplitter\n",
    "from neo4j_graphrag.experimental.pipeline.kg_builder import SimpleKGPipeline\n",
    "\n",
    "kg_builder_pdf = SimpleKGPipeline(\n",
    "    llm=ex_llm,\n",
    "    driver=driver,\n",
    "    text_splitter=FixedSizeSplitter(chunk_size=500, chunk_overlap=100),\n",
    "    embedder=embedder,\n",
    "    entities=node_labels,\n",
    "    relations=rel_types,\n",
    "    prompt_template=prompt_template,\n",
    "    from_pdf=True\n",
    ")"
   ],
   "id": "94e1dfac980e6527",
   "outputs": [],
   "execution_count": 5
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:46:37.876109Z",
     "start_time": "2024-10-12T23:37:59.301142Z"
    }
   },
   "cell_type": "code",
   "source": [
    "pdf_file_paths = ['truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf', \n",
    "             'truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf', \n",
    "             'truncated-pdfs/pgpm-13-39-trunc.pdf']\n",
    "\n",
    "for path in pdf_file_paths:\n",
    "    print(f\"Processing : {path}\")\n",
    "    pdf_result = await kg_builder_pdf.run_async(file_path=path)\n",
    "    print(f\"PDF Processing Result: {pdf_result}\")"
   ],
   "id": "edeee98826a970a8",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing : truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf\n",
      "PDF Processing Result: run_id='6f09563e-c0ba-44ce-bd7c-a8ce553f6d59' result={'resolver': {'number_of_nodes_to_resolve': 954, 'number_of_created_nodes': 732}}\n",
      "Processing : truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf\n",
      "PDF Processing Result: run_id='1b000f65-2a5d-4c07-aeb6-1f3cd3df8ab8' result={'resolver': {'number_of_nodes_to_resolve': 1042, 'number_of_created_nodes': 968}}\n",
      "Processing : truncated-pdfs/pgpm-13-39-trunc.pdf\n",
      "PDF Processing Result: run_id='260c1760-a78d-45ab-9d37-1b78ac8778e1' result={'resolver': {'number_of_nodes_to_resolve': 1814, 'number_of_created_nodes': 1621}}\n"
     ]
    }
   ],
   "execution_count": 6
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "## Knowledge Graph Retrieval",
   "id": "a9c0fd965b15b143"
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "We will leverage Neo4j's vector search capabilities here. To do this we need to begin by creating a vector index on the text in our Chunk nodes",
   "id": "4d7b98e310104246"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:46:38.533305Z",
     "start_time": "2024-10-12T23:46:37.876977Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.indexes import create_vector_index\n",
    "\n",
    "create_vector_index(driver, name=\"text_embeddings\", label=\"Chunk\",\n",
    "                    embedding_property=\"embedding\", dimensions=1536, similarity_fn=\"cosine\")"
   ],
   "id": "940b051107b89204",
   "outputs": [
    {
     "ename": "Neo4jIndexError",
     "evalue": "Neo4j vector index creation failed: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'.",
     "output_type": "error",
     "traceback": [
      "\u001B[0;31m---------------------------------------------------------------------------\u001B[0m",
      "\u001B[0;31mClientError\u001B[0m                               Traceback (most recent call last)",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j_graphrag/indexes.py:112\u001B[0m, in \u001B[0;36mcreate_vector_index\u001B[0;34m(driver, name, label, embedding_property, dimensions, similarity_fn, neo4j_database)\u001B[0m\n\u001B[1;32m    111\u001B[0m     logger\u001B[38;5;241m.\u001B[39minfo(\u001B[38;5;124mf\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mCreating vector index named \u001B[39m\u001B[38;5;124m'\u001B[39m\u001B[38;5;132;01m{\u001B[39;00mname\u001B[38;5;132;01m}\u001B[39;00m\u001B[38;5;124m'\u001B[39m\u001B[38;5;124m\"\u001B[39m)\n\u001B[0;32m--> 112\u001B[0m     driver\u001B[38;5;241m.\u001B[39mexecute_query(\n\u001B[1;32m    113\u001B[0m         query,\n\u001B[1;32m    114\u001B[0m         {\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mname\u001B[39m\u001B[38;5;124m\"\u001B[39m: name, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mdimensions\u001B[39m\u001B[38;5;124m\"\u001B[39m: dimensions, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124msimilarity_fn\u001B[39m\u001B[38;5;124m\"\u001B[39m: similarity_fn},\n\u001B[1;32m    115\u001B[0m         database_\u001B[38;5;241m=\u001B[39mneo4j_database,\n\u001B[1;32m    116\u001B[0m     )\n\u001B[1;32m    117\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m neo4j\u001B[38;5;241m.\u001B[39mexceptions\u001B[38;5;241m.\u001B[39mClientError \u001B[38;5;28;01mas\u001B[39;00m e:\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/driver.py:959\u001B[0m, in \u001B[0;36mDriver.execute_query\u001B[0;34m(self, query_, parameters_, routing_, database_, impersonated_user_, bookmark_manager_, auth_, result_transformer_, **kwargs)\u001B[0m\n\u001B[1;32m    958\u001B[0m \u001B[38;5;28;01mwith\u001B[39;00m session\u001B[38;5;241m.\u001B[39m_pipelined_begin:\n\u001B[0;32m--> 959\u001B[0m     \u001B[38;5;28;01mreturn\u001B[39;00m session\u001B[38;5;241m.\u001B[39m_run_transaction(\n\u001B[1;32m    960\u001B[0m         access_mode, TelemetryAPI\u001B[38;5;241m.\u001B[39mDRIVER,\n\u001B[1;32m    961\u001B[0m         work, (query_str, parameters, result_transformer_), {}\n\u001B[1;32m    962\u001B[0m     )\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/session.py:554\u001B[0m, in \u001B[0;36mSession._run_transaction\u001B[0;34m(self, access_mode, api, transaction_function, args, kwargs)\u001B[0m\n\u001B[1;32m    553\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 554\u001B[0m     result \u001B[38;5;241m=\u001B[39m transaction_function(tx, \u001B[38;5;241m*\u001B[39margs, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwargs)\n\u001B[1;32m    555\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m asyncio\u001B[38;5;241m.\u001B[39mCancelledError:\n\u001B[1;32m    556\u001B[0m     \u001B[38;5;66;03m# if cancellation callback has not been called yet:\u001B[39;00m\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/driver.py:1290\u001B[0m, in \u001B[0;36m_work\u001B[0;34m(tx, query, parameters, transformer)\u001B[0m\n\u001B[1;32m   1284\u001B[0m \u001B[38;5;28;01mdef\u001B[39;00m \u001B[38;5;21m_work\u001B[39m(\n\u001B[1;32m   1285\u001B[0m     tx: ManagedTransaction,\n\u001B[1;32m   1286\u001B[0m     query: te\u001B[38;5;241m.\u001B[39mLiteralString,\n\u001B[1;32m   1287\u001B[0m     parameters: t\u001B[38;5;241m.\u001B[39mDict[\u001B[38;5;28mstr\u001B[39m, t\u001B[38;5;241m.\u001B[39mAny],\n\u001B[1;32m   1288\u001B[0m     transformer: t\u001B[38;5;241m.\u001B[39mCallable[[Result], t\u001B[38;5;241m.\u001B[39mUnion[_T]]\n\u001B[1;32m   1289\u001B[0m ) \u001B[38;5;241m-\u001B[39m\u001B[38;5;241m>\u001B[39m _T:\n\u001B[0;32m-> 1290\u001B[0m     res \u001B[38;5;241m=\u001B[39m tx\u001B[38;5;241m.\u001B[39mrun(query, parameters)\n\u001B[1;32m   1291\u001B[0m     \u001B[38;5;28;01mreturn\u001B[39;00m transformer(res)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/transaction.py:172\u001B[0m, in \u001B[0;36mTransactionBase.run\u001B[0;34m(self, query, parameters, **kwparameters)\u001B[0m\n\u001B[1;32m    171\u001B[0m parameters \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mdict\u001B[39m(parameters \u001B[38;5;129;01mor\u001B[39;00m {}, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwparameters)\n\u001B[0;32m--> 172\u001B[0m result\u001B[38;5;241m.\u001B[39m_tx_ready_run(query, parameters)\n\u001B[1;32m    174\u001B[0m \u001B[38;5;28;01mreturn\u001B[39;00m result\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:171\u001B[0m, in \u001B[0;36mResult._tx_ready_run\u001B[0;34m(self, query, parameters)\u001B[0m\n\u001B[1;32m    167\u001B[0m \u001B[38;5;28;01mdef\u001B[39;00m \u001B[38;5;21m_tx_ready_run\u001B[39m(\u001B[38;5;28mself\u001B[39m, query, parameters):\n\u001B[1;32m    168\u001B[0m     \u001B[38;5;66;03m# BEGIN+RUN does not carry any extra on the RUN message.\u001B[39;00m\n\u001B[1;32m    169\u001B[0m     \u001B[38;5;66;03m# BEGIN {extra}\u001B[39;00m\n\u001B[1;32m    170\u001B[0m     \u001B[38;5;66;03m# RUN \"query\" {parameters} {extra}\u001B[39;00m\n\u001B[0;32m--> 171\u001B[0m     \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_run(query, parameters, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:221\u001B[0m, in \u001B[0;36mResult._run\u001B[0;34m(self, query, parameters, db, imp_user, access_mode, bookmarks, notifications_min_severity, notifications_disabled_classifications)\u001B[0m\n\u001B[1;32m    220\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_connection\u001B[38;5;241m.\u001B[39msend_all()\n\u001B[0;32m--> 221\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_attach()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:409\u001B[0m, in \u001B[0;36mResult._attach\u001B[0;34m(self)\u001B[0m\n\u001B[1;32m    408\u001B[0m \u001B[38;5;28;01mwhile\u001B[39;00m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_attached \u001B[38;5;129;01mis\u001B[39;00m \u001B[38;5;28;01mFalse\u001B[39;00m:\n\u001B[0;32m--> 409\u001B[0m     \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_connection\u001B[38;5;241m.\u001B[39mfetch_message()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_common.py:178\u001B[0m, in \u001B[0;36mConnectionErrorHandler.__getattr__.<locals>.outer.<locals>.inner\u001B[0;34m(*args, **kwargs)\u001B[0m\n\u001B[1;32m    177\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 178\u001B[0m     func(\u001B[38;5;241m*\u001B[39margs, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwargs)\n\u001B[1;32m    179\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m (Neo4jError, ServiceUnavailable, SessionExpired) \u001B[38;5;28;01mas\u001B[39;00m exc:\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_bolt.py:860\u001B[0m, in \u001B[0;36mBolt.fetch_message\u001B[0;34m(self)\u001B[0m\n\u001B[1;32m    857\u001B[0m tag, fields \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39minbox\u001B[38;5;241m.\u001B[39mpop(\n\u001B[1;32m    858\u001B[0m     hydration_hooks\u001B[38;5;241m=\u001B[39m\u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39mresponses[\u001B[38;5;241m0\u001B[39m]\u001B[38;5;241m.\u001B[39mhydration_hooks\n\u001B[1;32m    859\u001B[0m )\n\u001B[0;32m--> 860\u001B[0m res \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_process_message(tag, fields)\n\u001B[1;32m    861\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39midle_since \u001B[38;5;241m=\u001B[39m monotonic()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_bolt5.py:370\u001B[0m, in \u001B[0;36mBolt5x0._process_message\u001B[0;34m(self, tag, fields)\u001B[0m\n\u001B[1;32m    369\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 370\u001B[0m     response\u001B[38;5;241m.\u001B[39mon_failure(summary_metadata \u001B[38;5;129;01mor\u001B[39;00m {})\n\u001B[1;32m    371\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m (ServiceUnavailable, DatabaseUnavailable):\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_common.py:245\u001B[0m, in \u001B[0;36mResponse.on_failure\u001B[0;34m(self, metadata)\u001B[0m\n\u001B[1;32m    244\u001B[0m Util\u001B[38;5;241m.\u001B[39mcallback(handler)\n\u001B[0;32m--> 245\u001B[0m \u001B[38;5;28;01mraise\u001B[39;00m Neo4jError\u001B[38;5;241m.\u001B[39mhydrate(\u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mmetadata)\n",
      "\u001B[0;31mClientError\u001B[0m: {code: Neo.ClientError.Schema.EquivalentSchemaRuleAlreadyExists} {message: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'.}",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001B[0;31mNeo4jIndexError\u001B[0m                           Traceback (most recent call last)",
      "Cell \u001B[0;32mIn[7], line 3\u001B[0m\n\u001B[1;32m      1\u001B[0m \u001B[38;5;28;01mfrom\u001B[39;00m \u001B[38;5;21;01mneo4j_graphrag\u001B[39;00m\u001B[38;5;21;01m.\u001B[39;00m\u001B[38;5;21;01mindexes\u001B[39;00m \u001B[38;5;28;01mimport\u001B[39;00m create_vector_index\n\u001B[0;32m----> 3\u001B[0m create_vector_index(driver, name\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mtext_embeddings\u001B[39m\u001B[38;5;124m\"\u001B[39m, label\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mChunk\u001B[39m\u001B[38;5;124m\"\u001B[39m,\n\u001B[1;32m      4\u001B[0m                     embedding_property\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124membedding\u001B[39m\u001B[38;5;124m\"\u001B[39m, dimensions\u001B[38;5;241m=\u001B[39m\u001B[38;5;241m1536\u001B[39m, similarity_fn\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mcosine\u001B[39m\u001B[38;5;124m\"\u001B[39m)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j_graphrag/indexes.py:118\u001B[0m, in \u001B[0;36mcreate_vector_index\u001B[0;34m(driver, name, label, embedding_property, dimensions, similarity_fn, neo4j_database)\u001B[0m\n\u001B[1;32m    112\u001B[0m     driver\u001B[38;5;241m.\u001B[39mexecute_query(\n\u001B[1;32m    113\u001B[0m         query,\n\u001B[1;32m    114\u001B[0m         {\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mname\u001B[39m\u001B[38;5;124m\"\u001B[39m: name, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mdimensions\u001B[39m\u001B[38;5;124m\"\u001B[39m: dimensions, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124msimilarity_fn\u001B[39m\u001B[38;5;124m\"\u001B[39m: similarity_fn},\n\u001B[1;32m    115\u001B[0m         database_\u001B[38;5;241m=\u001B[39mneo4j_database,\n\u001B[1;32m    116\u001B[0m     )\n\u001B[1;32m    117\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m neo4j\u001B[38;5;241m.\u001B[39mexceptions\u001B[38;5;241m.\u001B[39mClientError \u001B[38;5;28;01mas\u001B[39;00m e:\n\u001B[0;32m--> 118\u001B[0m     \u001B[38;5;28;01mraise\u001B[39;00m Neo4jIndexError(\u001B[38;5;124mf\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mNeo4j vector index creation failed: \u001B[39m\u001B[38;5;132;01m{\u001B[39;00me\u001B[38;5;241m.\u001B[39mmessage\u001B[38;5;132;01m}\u001B[39;00m\u001B[38;5;124m\"\u001B[39m) \u001B[38;5;28;01mfrom\u001B[39;00m \u001B[38;5;21;01me\u001B[39;00m\n",
      "\u001B[0;31mNeo4jIndexError\u001B[0m: Neo4j vector index creation failed: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'."
     ]
    }
   ],
   "execution_count": 7
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Now that the index is set up we will start simple with a VectorRetriever.  The VectorRetriever just queries Chunk nodes, brining back the text and some metadata",
   "id": "ec95391c989ee694"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:49:41.996319Z",
     "start_time": "2024-10-12T23:49:41.483980Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.retrievers import VectorRetriever\n",
    "\n",
    "vector_retriever = VectorRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    return_properties=[\"text\"],\n",
    ")"
   ],
   "id": "eeda7e519c60a02b",
   "outputs": [],
   "execution_count": 8
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:51:21.382860Z",
     "start_time": "2024-10-12T23:51:20.783265Z"
    }
   },
   "cell_type": "code",
   "source": [
    "vector_res = vector_retriever.get_search_results(query_text = \"How is precision medicine applied to Lupus?\", \n",
    "                                                 top_k=3)\n",
    "for i in vector_res.records: print(\"====\\n\" + i.data()['node']['text'])"
   ],
   "id": "ca27731a1f99d71d",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====\n",
      "precise and systematic fashion as suggested here.\n",
      "Future care will involve molecular diagnostics throughout\n",
      "the patient timecourse to drive the least toxic combination\n",
      "of therapies. Recent evidence suggests a paradigm shift is\n",
      "on the way but it is hard to predict how fast it will come.\n",
      "Disclosure\n",
      "The authors report no con ﬂicts of interest in this work.\n",
      "References\n",
      "1. Lisnevskaia L, Murphy G, Isenberg DA. Systemic lupus\n",
      "erythematosus. Lancet .2014 ;384:1878 –1888. doi:10.1016/S0140-\n",
      "6736(14)60128\n",
      "====\n",
      "d IS agents.\n",
      "Precision medicine consists of a tailored approach to\n",
      "each patient, based on genetic and epigenetic singularities,\n",
      "which in ﬂuence disease pathophysiology and drug\n",
      "response. Precision medicine in SLE is trying to address\n",
      "the need to assess SLE patients optimally, predict disease\n",
      "course and treatment response at diagnosis. Ideally every\n",
      "patient would undergo an initial evaluation that would\n",
      "proﬁle his/her disease, assessing the main pathophysiolo-\n",
      "gic pathway through biomarkers, ther\n",
      "====\n",
      "REVIEW\n",
      "T owards Precision Medicine in Systemic Lupus\n",
      "Erythematosus\n",
      "This article was published in the following Dove Press journal:\n",
      "Pharmacogenomics and Personalized Medicine\n",
      "Elliott Lever1\n",
      "Marta R Alves2\n",
      "David A Isenberg1\n",
      "1Centre for Rheumatology, Division of\n",
      "Medicine, University College Hospital\n",
      "London, London, UK;2Internal Medicine,\n",
      "Department of Medicine, Centro\n",
      "Hospitalar do Porto, Porto, PortugalAbstract: Systemic lupus erythematosus (SLE) is a remarkable condition characterised by\n",
      "diversit\n"
     ]
    }
   ],
   "execution_count": 11
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "The GraphRAG Python Package offers a whole host of other useful retrieval covering different patterns.\n",
    "\n",
    "Below we will use the VectorCypherRetriever which allows you to run a graph traversal after finding text chunks.  We will use the Cypher Query language to define the logic to traverse the graph.  \n",
    "\n",
    "As a simple starting point, lets traverse up to 2 hops out from each chunk and textualize the different relationships we pick up.  We will use something called a quantified path pattern to accomplish in this. "
   ],
   "id": "2b2ee3da2339365f"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:51:41.858446Z",
     "start_time": "2024-10-12T23:51:41.565371Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.retrievers import VectorCypherRetriever\n",
    "\n",
    "vc_retriever = VectorCypherRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    retrieval_query=\"\"\"\n",
    "//node = Chunk.  Go out 2-3 hops in the entity graph \n",
    "MATCH (node)<-[:FROM_CHUNK]-()-[rl:!FROM_CHUNK]-{1,2}()\n",
    "UNWIND rl AS r\n",
    "WITH DISTINCT r\n",
    "\n",
    "//Get the source document(s) from which each entity set was extracted (could be multiple)\n",
    "MATCH (sourceDoc:Document)<-[FROM_DOCUMENT]-()<-[:FROM_CHUNK]-(n)-[r]->(m)\n",
    "WITH n,r,m, apoc.text.join(collect(DISTINCT sourceDoc.path), ', ') AS sources\n",
    "\n",
    "// return textualize relations/triples\n",
    "RETURN n.name +\n",
    "   ' - ' + type(r) + '(' + coalesce(r.details, '') + ')' +  ' -> ' +\n",
    "   m.name AS fact\n",
    "\"\"\"\n",
    ")\n",
    "\n"
   ],
   "id": "caf84995e4bc8d4",
   "outputs": [],
   "execution_count": 12
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": [
    "from neo4j_graphrag.retrievers import VectorCypherRetriever\n",
    "\n",
    "vc_retriever = VectorCypherRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    retrieval_query=\"\"\"\n",
    "//node = Chunk.  Go out 2-3 hops in the entity graph \n",
    "MATCH  (sourceDoc:Document)<-[FROM_DOCUMENT]-(node)<-[:FROM_CHUNK]-()-[rl:!FROM_CHUNK]-{1,2}()\n",
    "UNWIND rl AS r\n",
    "WITH DISTINCT r, apoc.text.join(collect(DISTINCT sourceDoc.path), ', ') AS sources\n",
    "\n",
    "MATCH (n)-[r]->(m)\n",
    "\n",
    "// return textualize relations/triples\n",
    "RETURN n.name +\n",
    "   ' - ' + type(r) + '(' + coalesce(r.details, '') + ')' +  ' -> ' +\n",
    "   m.name AS fact\n",
    "\"\"\"\n",
    ")"
   ],
   "id": "2c81ad815a7b1bf9"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:51:46.539231Z",
     "start_time": "2024-10-12T23:51:45.239355Z"
    }
   },
   "cell_type": "code",
   "source": [
    "vc_res = vc_retriever.get_search_results(query_text = \"How is precision medicine applied to Lupus?\")\n",
    "\n",
    "print(f\"Retrieved {len(vc_res.records)} records. Previewing the first 50:\\n\")\n",
    "for i in vc_res.records[:50]: print(\"====\\n\" + i.data()['fact']) "
   ],
   "id": "4a1df583f2450f35",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Retrieved 764 records. Previewing the first 50:\n",
      "\n",
      "====\n",
      "Systemic lupus erythematosus - AUTHORED(Published in) -> N. Engl. J. Med.\n",
      "====\n",
      "Lisnevskaia L - AUTHORED() -> Systemic lupus erythematosus\n",
      "====\n",
      "Murphy G - AUTHORED() -> Systemic lupus erythematosus\n",
      "====\n",
      "Isenberg DA - AUTHORED() -> Systemic lupus erythematosus\n",
      "====\n",
      "Systemic lupus erythematosus - CITES(Published in) -> Lancet\n",
      "====\n",
      "Systemic lupus erythematosus - CITES(Systemic lupus erythematosus is discussed in the Lancet publication.) -> Lancet\n",
      "====\n",
      "Systemic lupus erythematosus - ASSOCIATED_WITH(SLE is characterized by aberrant activity of the immune system) -> Aberrant activity of the immune system\n",
      "====\n",
      "Immunological biomarkers - USED_FOR(Immunological biomarkers could diagnose and monitor disease activity in SLE) -> Systemic lupus erythematosus\n",
      "====\n",
      "Novel SLE biomarkers - DESCRIBES(Novel SLE biomarkers have been discovered through omics research) -> Systemic lupus erythematosus\n",
      "====\n",
      "Lindblom et al. post-hoc analysis of BLISS-52 and BLISS-76 - AUTHORED(Lindblom et al. performed analysis on SLE patients) -> SLE\n",
      "====\n",
      "Lindblom et al. post-hoc analysis of BLISS-52 and BLISS-76 - AFFECTS(Association found between EQ-5D Full Health State and organ damage accrual) -> reduced subsequent organ damage accrual\n",
      "====\n",
      "Lindblom et al. post-hoc analysis of BLISS-52 and BLISS-76 - RESULTS_IN(Follow-up duration of 8 years for SLE patients receiving belimumab) -> 8 years of follow-up\n",
      "====\n",
      "current study - AUTHORED(Current study authored on SLE) -> SLE\n",
      "====\n",
      "SLE - INCLUDES(SLE includes QoL considerations in management) -> QoL\n",
      "====\n",
      "SLE - INCLUDES(Common biomarkers for SLE) -> biomarkers\n",
      "====\n",
      "biomarkers - ASSOCIATED_WITH(Biomarkers play a crucial role in diagnosing SLE.) -> SLE\n",
      "====\n",
      "biomarkers - ASSOCIATED_WITH(Biomarkers are used in the diagnosis process.) -> diagnosis\n",
      "====\n",
      "biomarkers - ASSOCIATED_WITH(Biomarkers are used in the context of diabetes.) -> diabetes\n",
      "====\n",
      "biomarkers - ASSOCIATED_WITH(Biomarkers are used in the context of heart disease.) -> heart disease\n",
      "====\n",
      "biomarkers - ASSOCIATED_WITH(Biomarkers are used in the context of cancer.) -> cancer\n",
      "====\n",
      "biomarkers - ASSOCIATED_WITH(Biomarkers are used in the prediction process.) -> prediction\n",
      "====\n",
      "biomarkers - ASSOCIATED_WITH(Biomarkers are used in the assessment process.) -> assessment\n",
      "====\n",
      "biomarkers - ASSOCIATED_WITH(Biomarkers are used in the management process.) -> management\n",
      "====\n",
      "biomarkers - ASSESSES(Biomarkers could assess organ-speciﬁc involvement in patients with SLE.) -> organ-speciﬁc involvement\n",
      "====\n",
      "assessing pathophysiologic pathway - PRODUCES(Assessing pathophysiologic pathway produces biomarkers) -> biomarkers\n",
      "====\n",
      "biomarkers - USED_FOR(Biomarkers are used for diagnosis) -> diagnosis\n",
      "====\n",
      "pathophysiologic pathway - RESULTS_IN(predicting risk of specific organ damage) -> biomarkers\n",
      "====\n",
      "Table 2 - CITES(Table 2 shows clinical and immunological biomarkers.) -> biomarkers\n",
      "====\n",
      "biomarkers - BIOMARKER_FOR(Biomarkers for SLE.) -> SLE\n",
      "====\n",
      "SLE - INCLUDES(B cells are responsible for antigen response in SLE.) -> B cells\n",
      "====\n",
      "B cells - ASSOCIATED_WITH(B cells are associated with double-negative B cells) -> double-negative B cells\n",
      "====\n",
      "B cells - ASSOCIATED_WITH(B cells are associated with ABC-like B cells) -> ABC-like B cells\n",
      "====\n",
      "SLE (Systemic Lupus Erythematosus) - ASSOCIATED_WITH(SLE is associated with lower CR2 expression) -> B cells\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE) - INCLUDES(SLE includes B cells) -> B cells\n",
      "====\n",
      "cellular recruitment - INCLUDES(cellular recruitment includes B cells.) -> B cells\n",
      "====\n",
      "Transcriptome in SLE - INCLUDES(The article includes analysis of B cells.) -> B cells\n",
      "====\n",
      "B cells - PRODUCES(B cells are responsible for antigen response.) -> antigen response\n",
      "====\n",
      "B cells - PRODUCES(B cells are responsible for cytokine production.) -> cytokine production\n",
      "====\n",
      "B cells - PRODUCES(B cells are responsible for the regulation of other cells.) -> regulation of other cells\n",
      "====\n",
      "B cells - EXPRESSES(B cells express somatic hypermutation.) -> somatic hypermutation\n",
      "====\n",
      "B cells - EXPRESSES(B cells express clonal expansion.) -> clonal expansion\n",
      "====\n",
      "complement receptor 2 (CR2) - EXPRESSES(CR2 is expressed on B cells) -> B cells\n",
      "====\n",
      "activated SLE B cells - EXPRESSES(activated SLE B cells express self-antigen presentation capability) -> B cells\n",
      "====\n",
      "early immature B cells - EXPRESSES(early immature B cells show increased activity) -> B cells\n",
      "====\n",
      "B cells - AFFECTS(B cells have impaired regulation in SLE) -> impaired regulation\n",
      "====\n",
      "B cells - AFFECTS(B cells have altered activation status in SLE) -> altered activation status\n",
      "====\n",
      "B cells - AFFECTS(B cells have altered response to antigen stimulation in SLE) -> altered response to antigen stimulation\n",
      "====\n",
      "B cells - INTERACTS_WITH(B cells interact with macrophages) -> macrophages\n",
      "====\n",
      "B cells - ACTIVATES(Local activation of B cells is correlated with an age-associated B-cell signature.) -> age-associated B-cell signature\n",
      "====\n",
      "B cells - COMPARED_WITH(SLE B cells are compared with healthy controls) -> healthy controls\n"
     ]
    }
   ],
   "execution_count": 13
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "## GraphRAG \n",
    " You can construct GraphRAG pipelines with the `GraphRAG` class.  At minimum, you will need to pass the constructor an LLM and a retriever. You can also pass a custom prompt template, but for now we will just use the default.\n",
    " "
   ],
   "id": "f2e55b8b3511cf1"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:57:58.847761Z",
     "start_time": "2024-10-12T23:57:58.813012Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.llm import OpenAILLM as LLM\n",
    "from neo4j_graphrag.generation.graphrag import GraphRAG\n",
    "\n",
    "llm = LLM(model_name=\"gpt-4o\",  model_params={\"temperature\": 0.0})\n",
    "\n",
    "v_rag  = GraphRAG(llm=llm, retriever=vector_retriever)\n",
    "vc_rag = GraphRAG(llm=llm, retriever=vc_retriever)"
   ],
   "id": "8e2cf317a83d59ae",
   "outputs": [],
   "execution_count": 27
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:55:17.821573Z",
     "start_time": "2024-10-12T23:55:11.465254Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"How is precision medicine applied to Lupus?\"\n",
    "print(f\"Vector Response: \\n{v_rag.search(q, retriever_config={'top_k':5}).answer}\")\n",
    "print(\"\\n===========================\\n\")\n",
    "print(f\"Vector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k':5}).answer}\")"
   ],
   "id": "4d0aff643e689611",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vector Response: \n",
      "Precision medicine in systemic lupus erythematosus (SLE) involves a tailored approach to each patient, based on their genetic and epigenetic characteristics, which influence disease pathophysiology and drug response. This approach aims to optimally assess SLE patients, predict disease course, and determine treatment response at diagnosis. Ideally, every patient would undergo an initial evaluation to profile their disease, assessing the main pathophysiologic pathway through biomarkers. The goal is to minimize the use of potent medications and their side effects while proactively treating autoimmunity and preventing damage. Future care is expected to involve molecular diagnostics throughout the patient's time course to drive the least toxic combination of therapies.\n",
      "\n",
      "===========================\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Precision medicine is applied to lupus, specifically systemic lupus erythematosus (SLE), by utilizing biomarkers to assess organ-specific involvement, which is crucial for precision medicine. The development of new strategies for monitoring and treating SLE contributes to precision medicine. Omics approaches, including transcriptome, epigenome, genome, and metabolome, provide opportunities for revealing new biomarkers for SLE, which are essential for precision medicine. Additionally, precision medicine involves the initial evaluation of profiling disease and assessing pathophysiologic pathways. The application of precision medicine in SLE is also associated with the analysis of B cell subsets and the use of multi-omics data from T cells.\n"
     ]
    }
   ],
   "execution_count": 23
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-12T23:55:31.581436Z",
     "start_time": "2024-10-12T23:55:17.824218Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"Can you summarize systemic lupus erythematosus (SLE)? including common effects, biomarkers, treatments, and current challenges faced by Physicians and patients? provide in list format with details for each item.\"\n",
    "print(f\"Vector Response: \\n{v_rag.search(q, retriever_config={'top_k': 5}).answer}\")\n",
    "print(\"\\n===========================\\n\")\n",
    "print(f\"Vector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k': 5}).answer}\")"
   ],
   "id": "d8afa42fcc8a475a",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vector Response: \n",
      "Certainly! Here's a summary of Systemic Lupus Erythematosus (SLE) including its common effects, biomarkers, treatments, and current challenges faced by physicians and patients:\n",
      "\n",
      "1. **Common Effects:**\n",
      "   - SLE imposes a significant burden on patients' lives, affecting their Health-Related Quality of Life (HRQoL).\n",
      "   - It is characterized by a wide range of symptoms due to immune reactivity and inflammation in various organs.\n",
      "\n",
      "2. **Biomarkers:**\n",
      "   - SLE is diagnosed and classified based on clinical symptoms, signs, and laboratory biomarkers.\n",
      "   - Common biomarkers reflect immune reactivity and inflammation, and are used to assess disease activity and therapeutic effects.\n",
      "   - Ideal biomarkers should reflect the underlying pathophysiology, have high reliability, validity, predictive values, sensitivity, and specificity.\n",
      "\n",
      "3. **Treatments:**\n",
      "   - A \"treat-to-target\" strategy is applied, aiming for remission and low disease activity.\n",
      "   - Despite this strategy, achieving these targets is not strongly associated with improved patient perception of health status.\n",
      "\n",
      "4. **Current Challenges:**\n",
      "   - There is a significant patient-clinician communication gap, with physicians focusing on disease activity control and patients on symptoms affecting HRQoL.\n",
      "   - The need for consistent classification criteria for research and clinical diagnosis.\n",
      "   - The challenge of finding ideal biomarkers that meet all necessary characteristics.\n",
      "   - Increasing patient engagement in disease management is recognized as important for improving health status perception.\n",
      "\n",
      "These points highlight the complexity of managing SLE and the need for improved communication and patient involvement in treatment strategies.\n",
      "\n",
      "===========================\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Certainly! Here's a summary of Systemic Lupus Erythematosus (SLE) including its common effects, biomarkers, treatments, and current challenges faced by physicians and patients:\n",
      "\n",
      "**Common Effects of SLE:**\n",
      "1. **Chronic Systemic Inflammation:** SLE causes widespread inflammation affecting multiple organs.\n",
      "2. **Organ Damage:** It can lead to damage in organs such as kidneys, heart, and skin.\n",
      "3. **Symptoms:** Common symptoms include fatigue, malar rash, diffuse alopecia, myalgia, fever, rash, cutaneous vasculitis, renal issues, pleurisy, and pericarditis.\n",
      "4. **Neuropsychiatric Symptoms:** SLE can cause cognitive dysfunction, mood disorders, and psychosis.\n",
      "5. **Cardiovascular Disease (CVD):** SLE is associated with increased risk of CVD due to endothelial damage and premature atherosclerosis.\n",
      "\n",
      "**Biomarkers for SLE:**\n",
      "1. **Anti-dsDNA Antibodies:** Used for diagnosis and monitoring disease activity.\n",
      "2. **Antiphospholipid Antibodies:** Associated with neuropsychiatric manifestations.\n",
      "3. **Complement Proteins (C3, C4):** Low levels are indicative of disease activity.\n",
      "4. **Anti-Sm Antibodies:** Highly specific for SLE diagnosis.\n",
      "5. **ANA (Antinuclear Antibodies):** Commonly used for screening and classification.\n",
      "6. **IFN, IL, IP-10, MCP-1:** Inflammatory markers associated with SLE activity.\n",
      "\n",
      "**Treatments for SLE:**\n",
      "1. **Antimalarials:** Used to manage symptoms and prevent flares.\n",
      "2. **Glucocorticoids (GC):** For controlling inflammation.\n",
      "3. **Immunosuppressants (IS):** To reduce immune system activity.\n",
      "4. **Biologics (e.g., Belimumab, Rituximab):** Target specific immune pathways.\n",
      "5. **Multidisciplinary Approach:** Involves various specialists to manage the disease comprehensively.\n",
      "\n",
      "**Current Challenges:**\n",
      "1. **Physicians:**\n",
      "   - **Disease Activity Control:** Focus on controlling disease activity and preventing damage accrual.\n",
      "   - **Communication Gap:** Ensuring effective communication with patients to align treatment goals.\n",
      "   - **Complex Pathophysiology:** Understanding the complex and heterogeneous nature of SLE.\n",
      "\n",
      "2. **Patients:**\n",
      "   - **Health-Related Quality of Life (HRQoL):** Managing symptoms and improving quality of life.\n",
      "   - **Treatment Side Effects:** Dealing with potential side effects and risks of long-term therapies.\n",
      "   - **Disease Burden:** Coping with the physical and emotional burden of chronic illness.\n",
      "\n",
      "**Current Research and Developments:**\n",
      "1. **Biomarker Studies:** Ongoing research to identify reliable biomarkers for diagnosis and monitoring.\n",
      "2. **Precision Medicine:** Efforts to tailor treatments based on individual genetic and biomarker profiles.\n",
      "3. **Patient-Reported Outcomes (PROs):** Increasing focus on incorporating patient perspectives in treatment plans.\n",
      "\n",
      "These points provide a comprehensive overview of SLE, highlighting its impact, diagnostic tools, therapeutic options, and the challenges faced by both healthcare providers and patients.\n"
     ]
    }
   ],
   "execution_count": 24
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-13T00:03:58.462510Z",
     "start_time": "2024-10-13T00:03:44.053866Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"Can you summarize systemic lupus erythematosus (SLE)? including common effects, biomarkers, and treatments? Provide in detailed list format\"\n",
    "print(f\"Vector Response: \\n{v_rag.search(q, retriever_config={'top_k': 5}).answer}\")\n",
    "print(\"\\n===========================\\n\")\n",
    "print(f\"Vector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k': 5}).answer}\")"
   ],
   "id": "a2c44f834bdb13ad",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vector Response: \n",
      "Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by the following:\n",
      "\n",
      "1. **Common Effects:**\n",
      "   - Aberrant activity of the immune system.\n",
      "   - Wide range of clinical manifestations.\n",
      "   - Can cause damage to various organs.\n",
      "   - Complex pathogenesis and heterogeneous clinical symptoms.\n",
      "\n",
      "2. **Biomarkers:**\n",
      "   - Biomarkers are used for diagnosing and monitoring disease activity in SLE.\n",
      "   - Ideal biomarkers should reflect the underlying pathophysiology or treatment target, have reliability, validity, high predictive values, and high sensitivity and specificity.\n",
      "   - Common biomarkers reflect immune reactivity and inflammation in various organs.\n",
      "   - Reproducibility and reliability of biomarkers may be affected by laboratory errors, specific techniques, or changes in storage.\n",
      "   - One particular biomarker may only reflect one specific aspect of SLE and may not be useful for reflecting the state of the disease as a whole.\n",
      "\n",
      "3. **Treatments:**\n",
      "   - Treatments aim to assess SLE disease activity and reflect the therapeutic effect of interventions.\n",
      "   - Consistent classification criteria for SLE are necessary for research and clinical diagnosis.\n",
      "   - The American College of Rheumatology (ACR) has established widely used classification criteria for SLE, which include laboratory biomarkers.\n",
      "\n",
      "Overall, SLE imposes a significant burden on patients' lives, affecting their health-related quality of life.\n",
      "\n",
      "===========================\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Certainly! Here's a detailed summary of Systemic Lupus Erythematosus (SLE), including its common effects, biomarkers, and treatments:\n",
      "\n",
      "### Common Effects of SLE:\n",
      "1. **Aberrant Immune Activity**: SLE is characterized by aberrant activity of the immune system, leading to a wide range of clinical manifestations.\n",
      "2. **Symptoms**:\n",
      "   - **Renal Symptoms**: Includes nephritis and proteinuria.\n",
      "   - **Dermatological Symptoms**: Skin lesions and cutaneous lupus.\n",
      "   - **Neuropsychiatric Symptoms**: Cognitive dysfunction, mood disorders, and psychosis.\n",
      "   - **Cardiovascular Symptoms**: Accelerated atherosclerosis and cardiovascular disease.\n",
      "   - **Hematological Problems**: Thrombocytopenia and hemolytic anemia.\n",
      "   - **General Symptoms**: Fatigue, widespread body pain, depression, anxiety, and sleep disturbance.\n",
      "3. **Organ Damage**: SLE can cause multiple organ damage, including kidney and cardiovascular systems.\n",
      "4. **Inflammation**: SLE is associated with chronic inflammation and endothelial damage.\n",
      "5. **Quality of Life**: SLE affects patients' health-related quality of life (HRQoL) and can lead to increased susceptibility to infections.\n",
      "\n",
      "### Biomarkers for SLE:\n",
      "1. **Immunological Biomarkers**: Used for diagnosing and monitoring disease activity.\n",
      "   - **Anti-dsDNA Antibodies**: Associated with disease activity and lupus nephritis.\n",
      "   - **Anti-Sm Antibodies**: Highly specific for SLE classification.\n",
      "   - **ANA (Antinuclear Antibodies)**: Used for screening and classification.\n",
      "   - **Complement Proteins (C3, C4)**: Low levels affect diagnosis specificity.\n",
      "   - **Anti-C1q Antibodies**: Associated with renal flares and lupus nephritis.\n",
      "2. **Potential Diagnostic Biomarkers**:\n",
      "   - **L-valine, L-leucine, Pyrimidine, Erucamide**: Identified through metabolome analysis.\n",
      "   - **IFI44L Methylation**: Diagnostic marker for SLE.\n",
      "3. **Other Biomarkers**:\n",
      "   - **Paraoxonase 1**: Key biomarker for accelerated atherosclerosis.\n",
      "   - **Monocyte-to-High-Density Lipoprotein Cholesterol Ratio**: Biomarker for CVD risk in SLE patients.\n",
      "\n",
      "### Treatments for SLE:\n",
      "1. **Medications**:\n",
      "   - **Glucocorticoids (e.g., Prednisone)**: Used to reduce inflammation.\n",
      "   - **Immunosuppressants (IS)**: To control immune system activity.\n",
      "   - **Antimalarials**: Commonly used for SLE management.\n",
      "   - **Biologics**:\n",
      "     - **Belimumab**: Targets B cells and improves quality of life.\n",
      "     - **Rituximab**: Used for severe cases and lupus nephritis.\n",
      "     - **Anifrolumab**: Studied for functional improvement in SLE.\n",
      "2. **Treatment Strategies**:\n",
      "   - **Treat-to-Target (T2T)**: Aims for remission or low disease activity.\n",
      "   - **Patient-Physician Communication**: Important for effective management and treatment adherence.\n",
      "3. **Monitoring and Management**:\n",
      "   - **Regular Monitoring**: Using biomarkers to track disease activity and treatment response.\n",
      "   - **Quality of Life Considerations**: Addressing symptoms like fatigue and pain to improve HRQoL.\n",
      "\n",
      "SLE is a complex autoimmune disease with a wide range of symptoms and effects, requiring a comprehensive approach to diagnosis, monitoring, and treatment.\n"
     ]
    }
   ],
   "execution_count": 37
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-13T00:20:30.233659Z",
     "start_time": "2024-10-13T00:20:15.650608Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"Can you summarize systemic lupus erythematosus (SLE)? including common effects, biomarkers, treatments, and current challenges faced by Physicians and patients? provide in list format with details for each item.\"\n",
    "print(f\"Vector Response: \\n{v_rag.search(q, retriever_config={'top_k': 5}).answer}\")\n",
    "print(\"\\n===========================\\n\")\n",
    "print(f\"Vector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k': 5}).answer}\")"
   ],
   "id": "d03ec43f6f02f608",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vector Response: \n",
      "Certainly! Here's a summary of Systemic Lupus Erythematosus (SLE) including its common effects, biomarkers, treatments, and current challenges faced by physicians and patients:\n",
      "\n",
      "1. **Common Effects:**\n",
      "   - SLE imposes a significant burden on patients' lives, affecting their Health-Related Quality of Life (HRQoL).\n",
      "   - Patients experience a range of symptoms that impact daily living, which may include fatigue, joint pain, skin rashes, and organ involvement.\n",
      "\n",
      "2. **Biomarkers:**\n",
      "   - SLE is diagnosed and classified based on clinical symptoms, signs, and laboratory biomarkers.\n",
      "   - Common biomarkers reflect immune reactivity and inflammation in various organs.\n",
      "   - Ideal biomarkers should reflect the underlying pathophysiology, have high reliability, validity, predictive values, sensitivity, and specificity.\n",
      "\n",
      "3. **Treatments:**\n",
      "   - A \"treat-to-target\" strategy is applied, aiming for remission and low disease activity.\n",
      "   - Treatments focus on controlling disease activity to prevent damage accrual.\n",
      "\n",
      "4. **Current Challenges:**\n",
      "   - There is a significant patient-clinician communication gap, with physicians focusing on disease activity and patients on symptoms affecting HRQoL.\n",
      "   - Reaching treatment targets is not strongly associated with improved patient perception of health status.\n",
      "   - There is a need for consistent classification criteria for research and clinical diagnosis.\n",
      "   - Engaging patients in disease management and improving communication are recognized as important for enhancing patients' health status perception.\n",
      "\n",
      "===========================\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Certainly! Here's a summary of Systemic Lupus Erythematosus (SLE) including its common effects, biomarkers, treatments, and current challenges faced by physicians and patients:\n",
      "\n",
      "**Common Effects of SLE:**\n",
      "1. **Chronic Systemic Inflammation:** SLE causes widespread inflammation affecting multiple organs.\n",
      "2. **Organ Damage:** It can lead to damage in organs such as the kidneys, heart, and skin.\n",
      "3. **Symptoms:** Common symptoms include fatigue, malar rash, diffuse alopecia, myalgia, fever, rash, cutaneous vasculitis, renal issues, pleurisy, and pericarditis.\n",
      "4. **Neuropsychiatric Symptoms:** SLE can cause cognitive dysfunction, mood disorders, and psychosis.\n",
      "5. **Cardiovascular Disease (CVD):** SLE is associated with an increased risk of CVD due to endothelial damage and premature atherosclerosis.\n",
      "\n",
      "**Biomarkers for SLE:**\n",
      "1. **Anti-dsDNA Antibodies:** Used for diagnosis and monitoring disease activity.\n",
      "2. **Antiphospholipid Antibodies:** Associated with neuropsychiatric manifestations.\n",
      "3. **Complement Proteins (C3, C4):** Low levels are indicative of disease activity.\n",
      "4. **Anti-Sm Antibodies:** Highly specific for SLE diagnosis.\n",
      "5. **ANA (Antinuclear Antibodies):** Commonly used for screening and classification.\n",
      "6. **Other Biomarkers:** Include IFN, IL, IP-10, MCP-1, and TNF.\n",
      "\n",
      "**Treatments for SLE:**\n",
      "1. **Antimalarials:** Used to manage symptoms and prevent flares.\n",
      "2. **Glucocorticoids (GC):** For controlling inflammation.\n",
      "3. **Immunosuppressants (IS):** To reduce immune system activity.\n",
      "4. **Biologics:** Such as Belimumab and Rituximab, targeting specific immune pathways.\n",
      "5. **Multidisciplinary Approach:** Involves surgery, physiotherapy, diet, exercise, and psychological support.\n",
      "\n",
      "**Current Challenges:**\n",
      "1. **Physicians:**\n",
      "   - **Disease Activity Control:** Focus on controlling disease activity and preventing damage accrual.\n",
      "   - **Communication Gap:** Challenges in aligning treatment goals with patient expectations.\n",
      "   - **Complex Pathophysiology:** Difficulty in understanding and managing the complex nature of SLE.\n",
      "\n",
      "2. **Patients:**\n",
      "   - **Health-Related Quality of Life (HRQoL):** SLE significantly impacts HRQoL due to chronic symptoms and organ damage.\n",
      "   - **Symptom Management:** Ongoing struggle with fatigue, pain, and other symptoms.\n",
      "   - **Treatment Side Effects:** Concerns about the side effects and potential risks of long-term therapies.\n",
      "   - **Communication with Physicians:** Patients often feel their concerns are not fully addressed, leading to a communication gap.\n",
      "\n",
      "**Current Research and Developments:**\n",
      "1. **Biomarker Studies:** Ongoing research to identify reliable biomarkers for better diagnosis and monitoring.\n",
      "2. **Precision Medicine:** Efforts to tailor treatments based on individual patient profiles and genetic information.\n",
      "3. **Patient-Reported Outcomes (PROs):** Increasing focus on incorporating PROs in treatment plans to improve patient satisfaction and outcomes.\n",
      "\n",
      "These points provide a comprehensive overview of SLE, highlighting its impact, diagnostic tools, treatment options, and the challenges faced by both healthcare providers and patients.\n"
     ]
    }
   ],
   "execution_count": 38
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": "",
   "id": "80cc3710ba067bec"
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
